1. Home
  2. TBPH vs ETON Comparison

TBPH vs ETON Comparison

Compare TBPH & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • ETON
  • Stock Information
  • Founded
  • TBPH 2013
  • ETON 2017
  • Country
  • TBPH United States
  • ETON United States
  • Employees
  • TBPH N/A
  • ETON N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • ETON Biotechnology: Pharmaceutical Preparations
  • Sector
  • TBPH Health Care
  • ETON Health Care
  • Exchange
  • TBPH Nasdaq
  • ETON Nasdaq
  • Market Cap
  • TBPH 464.5M
  • ETON 428.5M
  • IPO Year
  • TBPH N/A
  • ETON 2018
  • Fundamental
  • Price
  • TBPH $10.92
  • ETON $13.99
  • Analyst Decision
  • TBPH Strong Buy
  • ETON Strong Buy
  • Analyst Count
  • TBPH 5
  • ETON 3
  • Target Price
  • TBPH $16.60
  • ETON $29.67
  • AVG Volume (30 Days)
  • TBPH 366.7K
  • ETON 644.9K
  • Earning Date
  • TBPH 08-04-2025
  • ETON 08-07-2025
  • Dividend Yield
  • TBPH N/A
  • ETON N/A
  • EPS Growth
  • TBPH N/A
  • ETON N/A
  • EPS
  • TBPH N/A
  • ETON N/A
  • Revenue
  • TBPH $65,266,000.00
  • ETON $48,327,000.00
  • Revenue This Year
  • TBPH $43.18
  • ETON $103.21
  • Revenue Next Year
  • TBPH N/A
  • ETON $51.34
  • P/E Ratio
  • TBPH N/A
  • ETON N/A
  • Revenue Growth
  • TBPH 6.11
  • ETON 40.88
  • 52 Week Low
  • TBPH $7.44
  • ETON $3.22
  • 52 Week High
  • TBPH $11.82
  • ETON $21.48
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 60.52
  • ETON 37.00
  • Support Level
  • TBPH $10.46
  • ETON $13.09
  • Resistance Level
  • TBPH $11.44
  • ETON $14.61
  • Average True Range (ATR)
  • TBPH 0.27
  • ETON 0.76
  • MACD
  • TBPH -0.01
  • ETON 0.02
  • Stochastic Oscillator
  • TBPH 56.65
  • ETON 38.43

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Share on Social Networks: